Products are for research use only, not for human use

Protein or biologic

Somatropin

Somatropin is recombinant human growth hormone, originally produced in Escherichia coli: one chain of 191 amino acids matching the mature pituitary hormone. It is folded as a four-helix bundle and closed by two disulfide bonds.

Updated · 35 sources read · How this library is built

Static image of the Somatropin structure: Experimental X-ray structure at 2.8 Å: residues 1 to 190 of human growth hormone bound to two copies of the growth hormone receptor extracellular domain. PDB 3HHR, preferred over the 2.5 Å wild-type complex 1HWG because 3HHR's primary citation describes this complex while 1HWG's describes a receptor-binding mutant; 1HWG carries the full 191-residue construct and leaves the same loop unobserved.

Experimental, in a complex · Experimental X-ray structure at 2.8 Å: residues 1 to 190 of human growth hormone bound to two copies of the growth hormone receptor extracellular domain. PDB 3HHR, preferred over the 2.5 Å wild-type complex 1HWG because 3HHR's primary citation describes this complex while 1HWG's describes a receptor-binding mutant; 1HWG carries the full 191-residue construct and leaves the same loop unobserved.

Structure details
Source record
PDB 3HHR
Method
X-ray diffraction, 2.8 Å
Compound chain
auth A / label A
Also in the file
Two copies of the extracellular domain of the human growth hormone receptor, the fragment historically called the growth hormone binding protein: entity 2, label chains B and C, auth chains B and C.
Completeness
partial
Not modelled
Phe191, the C-terminal residue. The deposited entity sequence is 190 residues and matches the verified mature sequence character for character over positions 1 to 190, so the last residue is outside the deposited construct rather than modelled and disordered.; Residues 149 to 153 of the hormone (Asn-Ser-His-Asn-Asp) have no coordinates in the hormone chain.; Parts of both receptor chains are unmodelled. In the receptor entity numbering these are residues 26 to 30 and 43 in chain B along with its C-terminal 204 to 205, and residues 26 to 30 and 43 to 46 in chain C; the same residues are numbered 57 to 61, 74 and 235 to 236 in chain B and 57 to 61 and 74 to 77 in chain C in the deposited author numbering.
File
mmcif, retrieved 2026-11-02, sha256 088162b91d41731c...
Checks
pass: deposited construct is a declared-partial exact run of the entry sequence; pass: entity description recorded; pass: compound chain belongs to the named entity
  • This is the receptor-bound conformation of the hormone inside a crystal of a 1:2 complex. It is not a measurement of the free protein in solution.
  • No deposited structure of the free wild-type protein with the exact verified sequence was located. The entry titled as wild-type free hormone, 1HGU, carries a deposited sequence differing from the mature chain at twelve positions, which could not be reconciled against any record consulted and whose primary citation carries no PubMed identifier; the 2.0 Å free-hormone structure, 1HUW, is a 15-substitution phage-display variant.
  • An independent deposition of the wild-type protein in a 1:2 complex, 1HWG at 2.5 Å, does include Phe191 in its construct but leaves residues 148 to 153 and 191 unobserved, so the same loop is missing there too. Its primary citation describes the G120R antagonist mutant rather than the wild-type complex.
  • The complex contains only the receptor extracellular domains. Nothing of the transmembrane helix or the intracellular region is present, and no deposited structure of the whole membrane-embedded signalling assembly was located, so the step from binding to kinase activation is not something this view can show.
  • There is no computed database conformer either: the name resolves to no PubChem compound record.

Somatropin in brief

Somatropin is recombinant human growth hormone: a single 191-residue chain matching the mature pituitary hormone, with two disulfide bonds and no carbohydrate. It folds as a four-helix bundle and binds two copies of its receptor's extracellular domain in sequence, through two surfaces with sharply different binding energetics. Recombinant material made in Escherichia coli replaced pituitary-derived preparations from 1984. The binding step is unusually well characterised, almost entirely with purified extracellular domains rather than whole cells. No deposited structure of the free protein with this exact sequence exists, and materials with the same sequence have differed measurably in oxidation, deamidation and backbone cleavage.[1,2,3,4,5,6]

Somatropin regulatory status

Somatropin is an approved prescription biologic: in the United States licensed somatropin products are indicated for growth failure in children due to growth hormone deficiency and several other named conditions and for growth hormone deficiency in adults, two somatropin medicines are centrally authorised in the EU for comparable indications (a third authorisation was withdrawn and a fourth lapsed), and Health Canada lists marketed somatropin products as prescription drugs on Schedule D (all searched November 2026). United States federal law, 21 U.S.C. 333(e), makes it a criminal offence to distribute or possess with intent to distribute human growth hormone for any use in humans other than the treatment of a disease or other recognised medical condition, where that use has been authorised by the Secretary of Health and Human Services and is pursuant to the order of a physician. The WADA 2026 Prohibited List names growth hormone, its analogues and fragments under S2.2.3, in the class prohibited at all times. It is named neither in the FDA list of bulk drug substances that may present significant safety risks, which therefore records no agency concern against it, nor among the nominations that page lists as withdrawn (checked November 2026), and no retraction or expression of concern was found on any work cited here.[7,8,9,10,11,12,13]

Somatropin at a glance

  • One polypeptide chain of 191 L-amino acids, no carbohydrate, two disulfide bonds (Cys53 to Cys165 and Cys182 to Cys189), average mass about 22.1 kDa. The sequence is that of the mature pituitary hormone, which is why the protein is routinely called 22 kDa growth hormone.[1,14,15]
  • The fold is a four-helix bundle with an unusual topology, first described in the 1992 crystal structure of the hormone bound to its receptor. One hormone molecule binds two copies of the receptor extracellular domain, and it does so sequentially, a first receptor at site 1 and then a second at site 2. The two surfaces of the hormone have no structural similarity to each other, yet both receptors contribute essentially the same residues.[2,3]
  • The two interfaces are built on different energetic principles. At site 1 a small hydrophobic patch on the receptor, dominated by Trp104 and Trp169, carries more than three quarters of the binding free energy; that concentration is what a hot spot means, a few side chains accounting for most of the energy of an interface many residues wide. At site 2 no comparable hot spot exists and the important residues are spread across the whole surface. Both readings come from alanine scanning, which replaces one side chain at a time with the small methyl group of alanine and measures the change in binding, so it reports what a side chain contributes energetically rather than what it touches.[4,16,17,18]
  • Zinc is part of the molecular chemistry: two zinc ions bind per protein dimer through His18, His21 and Glu174, and adding zinc raised affinity for the prolactin receptor binding domain roughly 8000-fold in a binding assay.[19,20]
  • Because the sequence is short and unglycosylated, the identity of a given preparation is settled analytically rather than by inference, and materials that are nominally the same protein have been shown to differ measurably in methionine oxidation, deamidation at Asn149 and backbone cleavage.[6,15]

What is Somatropin?

Somatropin is the name given to recombinant human growth hormone when its chain matches the 191-residue mature pituitary protein exactly. The hormone itself was sequenced from pituitary material in the 1960s, and the published primary structure was revised in 1971 by two groups working at once, which is a useful reminder that the sequence now treated as settled was corrected before it was fixed. The same 1971 comparison showed that human placental lactogen matched growth hormone at around 80 percent of the residues examined, and that all three members of the family carry internal repeats, read then as evidence of descent from a smaller ancestral peptide by gene duplication.[21,22]

Where the hormone sits in the body is the context the rest of this page assumes. Growth hormone is made and released by the anterior pituitary under opposing hypothalamic control: growth hormone-releasing hormone drives its secretion and somatostatin restrains it, with ghrelin acting through its own receptor on the releasing-hormone neurones as a third input, and the output is pulsatile rather than steady. Downstream, the curated protein record states that the hormone's major role in stimulating body growth is to make the liver and other tissues secrete insulin-like growth factor 1, and that it also stimulates the differentiation and proliferation of myoblasts and amino acid uptake and protein synthesis in muscle and other tissues. The step between the receptor and those changes runs through the receptor-associated kinase JAK2 and the STAT transcription factors, which is why a mechanistic account of this receptor is an account of how ligand binding repositions a kinase rather than of how it opens a channel. That axis is also what joins this entry to its neighbours: growth hormone-releasing hormone analogues act one step upstream of this molecule and insulin-like growth factor 1 analogues one step downstream.[23,1,24]

The protein belongs to the ligands of the class 1 cytokine receptor family, and structurally it is a four-helix bundle: four long helices packed against each other with an unusual up-up-down-down connectivity, with two long crossover loops, one of which is pinned back by the larger disulfide bond. Its binding partner, the growth hormone receptor, is a single-pass membrane protein whose extracellular region of roughly 250 residues contains a fibronectin type-III domain and three disulfide bonds; the soluble fragment used in almost all of the structural work is that extracellular region, called the growth hormone binding protein in the older literature.[2,25,1]

Its production history is unusually relevant to its identity. The gene was expressed directly in Escherichia coli in 1979, from a hybrid construct combining chemically synthesised DNA with enzymatically prepared complementary DNA, and recombinant material replaced preparations purified from cadaveric pituitary tissue from 1984. Because growth hormone carries no sugars and only two disulfide bonds, a bacterial host can reproduce the natural covalent structure, and the molecule was well characterised physicochemically early: by the 1990s a series of collaborative studies had established that physicochemical methods detected structural degradation more selectively than the available bioassays, and a 1994 consensus replaced routine bioassay with physicochemical analysis for batch characterisation. Somatropin is therefore one of the few proteins whose identity in practice rests on chromatography and mass spectrometry rather than on a potency measurement.[5,15]

One further consequence of the gene is why identity is a real question here rather than a formality. The GH1 gene yields more than one protein: the 191-residue chain this entry is about, routinely called 22 kDa growth hormone, and a 20 kDa form made by an alternative splice acceptor site inside exon 3 that removes 45 base pairs and therefore 15 residues. A separate gene in the same cluster on chromosome 17 encodes the placental variant, also 22 kDa but differing at 13 residues scattered through the chain. Serum measurement by mass spectrometry treats the 22 kDa and 20 kDa forms as separate measurands for exactly that reason. Two further substances share the description without sharing the molecule: the 192-residue methionyl form, somatrem, and a polymer conjugate, each with its own registry record.[26,27,15,14,28]

The supplier catalogue rows behind this entry list the material only as HGH, in international units per vial. An international unit is a potency convention referred to a reference preparation, not a statement of sequence, mass or purity, so a listing of that kind identifies nothing on its own: the 20 kDa isoform, the 192-residue methionyl form and a chain carrying a thioether in place of its small disulfide would all be described the same way. Nothing on this page should be read as a statement about any particular material.[15,26,29]

Not to be confused with

Somatrem
A 192-residue methionyl form of the same protein, carrying an extra N-terminal methionine left over from bacterial expression. The review that defines somatropin as the 191-residue molecule explicitly treats somatrem as a separate substance outside its scope. One residue is the whole difference, and it is at the end of the chain that site 1 binding uses.[15,18]
The 20 kDa growth hormone isoform
A shorter natural form produced from the same gene by an alternative splice acceptor site within exon 3, which removes 45 base pairs and therefore 15 residues. It is a different protein, not a degradation product of somatropin, and mass spectrometry of serum treats the 22 kDa and 20 kDa forms as separate measurands precisely because their presence distinguishes one pool from another.[26,27]
Placental growth hormone variant (hGH-V)
The product of a separate gene in the same cluster. It is also 22 kDa but differs from the pituitary protein at 13 residues scattered through the chain, and in a side-by-side in vitro comparison its 20 kDa form showed reduced prolactin-receptor-mediated activity relative to the pituitary forms.[27]
Human prolactin and human placental lactogen
Relatives rather than the same molecule. Placental lactogen matched growth hormone at roughly 80 percent of the residues examined in the 1971 sequence comparison, and the three hormones carry internal homologies read as evidence of a shared ancestor. Growth hormone binds the prolactin receptor; prolactin does not bind the growth hormone receptor.[22,37,38]
hGH fragment 176-191
A short synthetic peptide corresponding to a stretch near the C-terminus of this protein. A 16-residue fragment cannot form the four-helix bundle, cannot present either receptor-binding surface and carries neither disulfide intact, so nothing established for the whole protein transfers to it.[2,1]
Engineered growth hormone variants used in the structural literature
Much of the highest-resolution work uses deliberate mutants: G120R, which binds one receptor instead of two, and phage-display variants carrying 5 to 15 substitutions. They are the molecules in several of the deposited structures and they are not somatropin, which is why the structure shown here is the wild-type complex.[16,33,36,35]
Long-acting and conjugated growth hormone analogues
The substance registry holds separate records for modified forms such as somatropin pegol, which carries a polymer conjugate. A conjugate has a different mass, a different hydrodynamic size and a modified surface, so it is a distinct substance with its own identifier rather than a formulation of this one.[14]

Somatropin structure and sequence

Reading the chain, the features that matter are sparse and well separated. Four cysteines form two bonds: Cys53 to Cys165, which clamps the long loop between the second and third helices against the bundle, and Cys182 to Cys189, which closes a six-residue loop near the C-terminus. Three methionines sit at positions 14, 125 and 170, three histidines at 18, 21 and 151, and the single tryptophan at position 86. His18 and His21 sit near one end of the first helix, and together with Glu174 near the C-terminus they form the zinc site, which is the clearest illustration that the folded protein brings distant parts of the sequence into one small cluster.[1,19,6]

The two receptor-binding surfaces are also discontinuous in sequence. The alanine scan that first mapped site 1 at residue resolution worked through three separate stretches, residues 2 to 19, 54 to 74 and 167 to 191, because those were the segments the earlier work had implicated; site 2 is a different face, centred on Asp116 and nearby residues. Neither surface can be recognised by reading the sequence, and neither can be reproduced by a fragment of it.[18,30]

The 3D view shows the hormone as it sits in the 1:2 complex with two copies of the receptor extracellular domain, at 2.8 Å. Two things it does not show are worth stating. The last residue, Phe191, is outside the deposited construct, and residues 149 to 153 have no coordinates, so the loop that carries His151 is absent from the model. More broadly, it is a bound conformation in a crystal: no deposited structure of the free protein with this exact sequence was located, since the free-hormone entry titled as wild-type has a deposited sequence differing at twelve positions and the high-resolution free-hormone structure is a fifteen-substitution variant. In that variant the first turn of the third core helix is unwound, which its authors attribute to crystal packing rather than to the mutations, and the model again breaks between residues 128 and 155. The same loop goes missing in three independent crystals, which is itself the finding: that region is mobile.[31,2,32,33,34]

Primary structure diagram of a 191-residue protein, each residue drawn as a circle carrying its one-letter code, laid out in six rows with position numbers every ten residues and two disulfide bonds drawn as vertical links between pairs of cysteines.
All 191 residues as one-letter codes with the numbering marked every ten, and both disulfide bonds drawn: the long one joining Cys53 to Cys165, which ties the middle of the chain to its carboxyl end, and the short one joining Cys182 to Cys189 near the tail. A skeletal drawing of a protein this size would be unreadable, so this is the right form of figure for it. Checked residue by residue against the sequence this page gives, from the phenylalanine at position one to the phenylalanine at 191. Benff, via Wikimedia Commons. CC0 · source
  1. F1
  2. P2
  3. T3
  4. I4
  5. P5
  6. L6
  7. S7
  8. R8
  9. L9
  10. F10
  11. D11
  12. N12
  13. A13
  14. M14
  15. L15
  16. R16
  17. A17
  18. H18
  19. R19
  20. L20
  21. H21
  22. Q22
  23. L23
  24. A24
  25. F25
  26. D26
  27. T27
  28. Y28
  29. Q29
  30. E30
  31. F31
  32. E32
  33. E33
  34. A34
  35. Y35
  36. I36
  37. P37
  38. K38
  39. E39
  40. Q40
  41. K41
  42. Y42
  43. S43
  44. F44
  45. L45
  46. Q46
  47. N47
  48. P48
  49. Q49
  50. T50
  51. S51
  52. L52
  53. C53
  54. F54
  55. S55
  56. E56
  57. S57
  58. I58
  59. P59
  60. T60
  61. P61
  62. S62
  63. N63
  64. R64
  65. E65
  66. E66
  67. T67
  68. Q68
  69. Q69
  70. K70
  71. S71
  72. N72
  73. L73
  74. E74
  75. L75
  76. L76
  77. R77
  78. I78
  79. S79
  80. L80
  81. L81
  82. L82
  83. I83
  84. Q84
  85. S85
  86. W86
  87. L87
  88. E88
  89. P89
  90. V90
  91. Q91
  92. F92
  93. L93
  94. R94
  95. S95
  96. V96
  97. F97
  98. A98
  99. N99
  100. S100
  101. L101
  102. V102
  103. Y103
  104. G104
  105. A105
  106. S106
  107. D107
  108. S108
  109. N109
  110. V110
  111. Y111
  112. D112
  113. L113
  114. L114
  115. K115
  116. D116
  117. L117
  118. E118
  119. E119
  120. G120
  121. I121
  122. Q122
  123. T123
  124. L124
  125. M125
  126. G126
  127. R127
  128. L128
  129. E129
  130. D130
  131. G131
  132. S132
  133. P133
  134. R134
  135. T135
  136. G136
  137. Q137
  138. I138
  139. F139
  140. K140
  141. Q141
  142. T142
  143. Y143
  144. S144
  145. K145
  146. F146
  147. D147
  148. T148
  149. N149
  150. S150
  151. H151
  152. N152
  153. D153
  154. D154
  155. A155
  156. L156
  157. L157
  158. K158
  159. N159
  160. Y160
  161. G161
  162. L162
  163. L163
  164. Y164
  165. C165
  166. F166
  167. R167
  168. K168
  169. D169
  170. M170
  171. D171
  172. K172
  173. V173
  174. E174
  175. T175
  176. F176
  177. L177
  178. R178
  179. I179
  180. V180
  181. Q181
  182. C182
  183. R183
  184. S184
  185. V185
  186. E186
  187. G187
  188. S188
  189. C189
  190. G190
  191. F191
One-letter code, all-L, positions 1 to 191 of the mature chain. This is residues 27 to 217 of the GH1 precursor in UniProt P01241, the 26-residue signal peptide having been removed; position 1 is the phenylalanine of the mature protein, and the chain ends in a free carboxylate at Phe191. The same 191-residue string is the single subunit recorded for somatropin in the FDA substance registry.. Outlined positions carry a modification listed below.

Modifications

  • Cys53 to Cys165 The large disulfide bond, which ties the long loop between the second and third core helices back to the body of the protein. Numbered 79 to 191 in the precursor numbering UniProt uses and 53 to 165 in the mature numbering used here and by the substance registry.[1,14]
  • Cys182 to Cys189 The small C-terminal disulfide bond, enclosing a short loop of six residues. It is the chemically vulnerable one: a variant isolated from bacterially expressed material had this bridge replaced by a non-reducible thioether, with the change detected by peptide mapping, de novo sequencing and near-UV circular dichroism.[1,14,29]
  • Whole chain No carbohydrate. The protein carries no N-linked or O-linked glycan, which is why a bacterially expressed chain can reproduce the natural sequence exactly and why the measured mass of intact material is compared directly against the sum over the sequence.[1,15]

All residues are the L enantiomers of the twenty proteinogenic amino acids, with no D-residues, no non-canonical residues and no cyclisation of the backbone. The only covalent cross-links are the two disulfide bonds, so the folded state is held almost entirely by non-covalent packing of the helix bundle. Separately from covalent structure, the protein binds zinc: two zinc ions associate per protein dimer in a cooperative fashion, cobalt(II) can substitute and gives a spectrum characteristic of tetrahedral coordination by oxygen and nitrogen ligands, and replacing His18, His21 or Glu174 with alanine weakened both metal binding and dimer formation. A zinc ion is present in the deposited growth hormone complex with the prolactin receptor extracellular domain.[19,20,1]

What studies on Somatropin show

Each card names the experimental system and what was measured. A result in one system is not evidence about another.

X-ray crystallography · Crystals of purified human growth hormone with the extracellular domain of the human growth hormone receptor

The complex contains one hormone per two receptor domains. The hormone is a four-helix bundle of unusual topology; each receptor domain comprises two subdomains with some resemblance to immunoglobulin folds but a different relative orientation, and both contribute residues to hormone binding. Both receptors donate essentially the same residues even though the two binding sites on the hormone have no structural similarity. There is also a substantial contact between the C-terminal subdomains of the two receptors, and the relative sizes of the interfaces support a sequential mechanism of assembly.[2]

Material
Wild-type hormone, residues 1 to 190 modelled, with two copies of the receptor extracellular domain (PDB 3HHR)
Measured
The structure of the complex at 2.8 Å, its stoichiometry, and the identity of the contact residues on both proteins
Compared with
Interfaces predicted by the earlier mutational mapping
Limitation
Isolated receptor extracellular domains in a crystal: no membrane, no transmembrane helix, no intracellular region, and no information about the free hormone in solution. Residues 149 to 153 are unmodelled and Phe191 is outside the construct.

de Vos AM et al., 1992, Science

Alanine-scanning mutagenesis with receptor binding measurement · Binding to the growth hormone receptor cloned from human liver

A cluster of about a dozen large side chains each lost more than fourfold affinity when replaced by alanine, defining site 1 at residue resolution. One residue behaved the opposite way: alanine at Glu174 raised affinity more than fourfold, so that side chain hinders binding in the wild-type protein. Many of the residues that promote binding differ in placental lactogens and prolactins, which do not bind this receptor tightly.[18]

Material
62 single alanine substitutions covering every residue in positions 2 to 19, 54 to 74 and 167 to 191
Measured
Change in receptor binding affinity for each single mutant
Compared with
Wild-type hormone; folding checked against seven conformation-sensitive monoclonal antibodies
Limitation
Affinity for one receptor, measured before any structure existed. Alanine scanning reports the energetic contribution of a side chain and not contact geometry, and the antibody check establishes that the fold survived rather than that nothing moved locally.

Cunningham BC et al., 1989, Science

Solution biophysics: size-exclusion chromatography, calorimetry, fluorescence quenching · Purified hormone with the receptor extracellular binding protein

The hormone forms a 1:2 complex with the receptor extracellular domain, and binding is sequential: a first receptor binds site 1, then a second binds the adjacent but distinct site 2. Two overlapping surfaces on the receptor were implicated in binding the hormone.[3]

Material
Wild-type hormone plus engineered variants
Measured
Complex stoichiometry, the order of binding, and which hormone residues belong to which site
Compared with
Variants altered at each of the two candidate surfaces
Limitation
Isolated extracellular domains in solution. Receptor dimerisation is proposed to be relevant to signalling; the study measures assembly, not signalling.

Cunningham BC et al., 1991, Science

Alanine scan of the receptor side, read against the crystal structure · Receptor extracellular domain mutants binding the hormone

About 30 side chains from each protein are in contact, but a central hydrophobic region dominated by two tryptophans accounts for more than three quarters of the binding free energy. The surrounding contacts are generally hydrophilic and partially hydrated, so the interface resembles a cross section through a globular protein with a packed core and a wet rim. The functionally important receptor residues contact the functionally important hormone residues directly.[4]

Material
Individual alanine replacements of receptor contact residues
Measured
Contribution of each contact residue to binding free energy
Compared with
Wild-type receptor domain; the structural contact set from the crystal
Limitation
Energetics inferred from binding measurements on mutants rather than from structures of each mutant, and the scan is of the receptor, so it defines the hormone's partner surface rather than the hormone's own.

Clackson T et al., 1995, Science

X-ray crystallography at 2.6 Å with binding and kinetic analysis · Crystals of a 1:1 hormone-receptor complex, plus mutant binding kinetics

The 1:1 complex closely resembles the corresponding part of the 1:2 complex, so assembling the active complex does not require a major conformational change. A segment that makes receptor-receptor contact in the 1:2 complex is disordered here, which suggests its ordered conformation is stabilised by the second receptor. The hot spot is assembled cooperatively: several hydrophobic residues serve mainly to orient Trp104 and Trp169, and the directly energetic epitope may comprise as few as six side chains, mostly in alkyl-aromatic stacking. Replacing seven peripheral residues with alanine raised affinity up to tenfold, so the rim attenuates rather than adds to the central interaction.[16]

Material
G120R hormone, which can bind only one receptor, with the receptor extracellular domain (PDB 1A22)
Measured
Whether forming the complex changes either protein's conformation, and how the site 1 hot spot is assembled
Compared with
The equivalent portion of the wild-type 1:2 complex
Limitation
The hormone here is an engineered single substitution, G120R, chosen because it cannot bind a second receptor, so it is not somatropin and the site 2 surface is deliberately disabled.

Clackson T et al., 1998, Journal of Molecular Biology

Trimolecular surface plasmon resonance kinetics · Binding of a second receptor extracellular domain to a preassembled 1:1 hormone-receptor complex

Site 2 has no distinct hot spot. Its important residues are distributed over the whole binding surface rather than clustered, and pairwise alanine mutations showed significant negative cooperativity, including between residues more than 10 Å apart: substitutions that alone did little, or even improved binding, behaved differently when paired with the Asp116 substitution. The second interface is therefore both structurally and energetically malleable, in contrast to site 1.[17]

Material
38 single and double alanine mutants in the hormone's site 2 surface
Measured
Association and dissociation kinetics for the second binding step
Compared with
Wild-type hormone; pairwise double mutants against the single mutants
Limitation
Kinetics on isolated extracellular domains with no cellular or signalling readout, and cooperativity is inferred from binding energies rather than observed structurally.

Walsh ST et al., 2003, Protein Science

Metal binding and protein association: size-exclusion chromatography, sedimentation equilibrium, radiolabelled zinc Scatchard analysis, cobalt substitution spectroscopy, denaturation · Purified hormone in solution

Zinc induced dimerisation, with two zinc ions per hormone dimer bound cooperatively. Cobalt(II) substituted and produced a visible spectrum characteristic of tetrahedral coordination by oxygen- and nitrogen-containing ligands. Alanine at His18, His21 or Glu174 weakened both metal binding and dimer formation, identifying those three side chains as the ligands. The zinc-bound dimer resisted chemical denaturation better than the monomer.[19]

Material
Wild-type hormone and His18, His21 and Glu174 alanine mutants
Measured
Zinc stoichiometry and cooperativity, metal coordination geometry, dimer formation, and resistance to guanidine hydrochloride denaturation
Compared with
Hormone without added zinc; cobalt(II) in place of zinc
Limitation
In vitro with metal added as an assay condition. The suggestion that this matters for storage in secretory granules is a proposal in the paper, not a measurement in it.

Cunningham BC et al., 1991, Science

Liquid chromatography with online tandem mass spectrometry · Recombinant human growth hormone material from three sources, described by the authors as innovator, follow-on and counterfeit

All three materials gave the expected sequence and disulfide pattern, yet differed measurably in chemistry: methionine oxidation followed the order Met14, then Met125, then Met170 in each case, with the follow-on material the most oxidised and the innovator material the least; deamidation at Asn149 was lowest in the follow-on and highest in the counterfeit; and backbone cleavage was site-specific, between Asn99 and Ser100 or between Glu30 and Phe31 depending on the source. The authors attribute the differences to manufacturing, formulation and storage rather than to sequence.[6]

Material
Intact protein digested for peptide mapping, with accurate mass and fragment-based sequence assignment
Measured
Complete sequence coverage with disulfide linkages, and the extent of oxidation, deamidation and chain cleavage at each site
Compared with
The three materials against each other; modified against unmodified peptide peak areas
Limitation
One sample per source, with the counterfeit material unidentified as to origin. The measurements are of chemical modification only and establish nothing about receptor binding or any functional property.

Jiang H et al., 2009, Biotechnology Progress

Mechanistic model of kinase activation from resonance energy transfer, engineered receptor constructs, atomistic simulation and domain docking · The growth hormone receptor treated as an archetypal cytokine receptor: fluorescence resonance energy transfer to report the position of the JAK2 binding motif in the receptor dimer, receptor extracellular domains replaced by Jun zippers to control the relative position of the transmembrane helices, atomistic modelling of those helix movements, and docking of the separately determined JAK2 kinase and inhibitory pseudokinase structures against an opposing pair

A complete mechanistic model for activation of receptor-bound JAK2, in which the activating event is a change in the relative position of the two transmembrane helices that separates the two JAK2 binding motifs and so breaks an inhibitory pairing between one receptor's kinase domain and the other's pseudokinase domain. This is the step the binding work on this page stops short of, and it is the reason simply bringing two receptors together is not sufficient.[24]

Material
Engineered receptor constructs, not the hormone: somatropin enters only as the physiological trigger the model has to account for
Measured
Position of the JAK2 binding motif within the receptor dimer, transmembrane helix movement, and the arrangement of kinase and pseudokinase domains
Compared with
Zipper constructs holding the transmembrane helices in defined relative positions, read against the arrangement a ligand produces
Limitation
The molecule under test is the receptor and not somatropin, which is absent from the constructs that carry the argument, and the kinase arrangement is docked from structures determined separately rather than observed in one assembly. No deposited structure of a hormone-bound, membrane-spanning receptor with its kinase was located, so the hormone's own contribution is still attributed rather than observed: it is the asymmetric placement of its two binding sites.

Brooks AJ et al., 2014, Science

How somatropin is studied at its own receptor and at the prolactin receptor

The molecular account is unusually complete for the binding step and deliberately incomplete after it. One hormone molecule recruits two copies of the receptor extracellular domain in order, site 1 first and then site 2, and the crystal structures of the 1:2 and 1:1 complexes are close enough that assembly requires no large conformational change in either protein. The hormone's two binding faces are not variations on one surface: they share no structural similarity, they are read by the same set of receptor residues, and they are energetically quite different, with a compact tryptophan-dominated hot spot at site 1 and a diffuse, malleable surface at site 2.[3,2,16,4,17]

The two sites are not independent. Mutagenesis across 81 single and 32 double positions showed that changes at site 1 reorganise site 2 both conformationally and energetically, focused on the contact between hormone Asp116 and receptor Trp169, and in that work the reorganisation happened without a loss of overall affinity. The crystal structure of a fifteen-substitution site 1 variant with two receptor domains makes the same point structurally: only one of ten hydrogen bonds in site 1 survived the substitutions, parts of the hormone moved by up to 9 Å, and site 2 was extensively rebuilt although no mutations were made there. A separate experiment, deleting a tryptophan from the receptor to create a cavity and selecting a hormone pentamutant that fills it, produced large rearrangements at interface positions distant from any mutation. The interface is plastic rather than lock-and-key.[30,35,36]

The same molecule also binds a second receptor, and the comparison is informative about specificity. Growth hormone binds the prolactin receptor while prolactin does not bind the growth hormone receptor, and mutagenesis had shown the two receptor-binding sites on the hormone overlap, which the crystal structure of the hormone with the prolactin receptor extracellular domain then explained as one hormone surface accommodating two different receptor surfaces. That interaction is metal-dependent in a way the hormone's own receptor is not: added zinc raised affinity for the prolactin receptor binding domain about 8000-fold, with one zinc per complex and His18, His21 and Glu174 on the hormone plus a histidine on the receptor implicated as its ligands, while zinc was required neither for growth hormone at its own receptor nor for prolactin at the prolactin receptor. A later kinetic study found a further asymmetry at that shared receptor: prolactin's dissociation rate changed 500-fold between pH 8.3 and 5.8 whereas growth hormone binding to the same receptor domain showed no significant pH dependence.[37,20,38]

An abstract illustration standing for the kind of process this entry describes. It depicts no molecule and carries no text.
An abstract illustration, chosen to suit the kind of process this page describes. It is decoration rather than evidence: nothing in it is specific to this compound, nothing in it was measured, and it depicts no molecule. Generated from this entry's topic list. Volta Peptides compound library. CC0 1.0

What is still unknown about Somatropin

There is no deposited structure of the free protein with the verified sequence. The entry titled as the wild-type free hormone carries a deposited sequence differing from the mature chain at twelve positions, a discrepancy no record consulted here explains and whose primary citation has no PubMed identifier; the highest-resolution free-hormone structure is a fifteen-substitution affinity-matured variant. Everything structural about somatropin itself therefore comes from complexes, and three independent crystals leave the loop around residues 149 to 153 unmodelled, so that region's conformation is unknown rather than known to be flexible in a described way.[32,33,31,34]

Two of the most quoted facts about this molecule rest on a single record each, and one of them is internally inconsistent. The FDA substance registry states a molecular formula that disagrees with a sum over its own stated sequence by two hydrogens and one oxygen, while its molecular weight matches the sum; the summed formula is printed here and the disagreement is recorded rather than resolved. Separately, three of the nine identifiers on this page (DrugBank, IUPHAR/BPS and the ChEBI class term) are cross-references read from that one registry record rather than from the databases themselves, and the ChEBI term in particular resolves to a general class, not to this 191-residue protein. The ChEMBL identifier was a fourth until that record was read at source, where it resolves to somatropin typed as a protein.[14,1,39,40]

Covalent identity and chemical identity are not the same question, and the literature on this protein is unusually explicit about the gap. Material from three sources, all nominally the same protein with the same sequence and the same disulfide pattern, differed measurably in methionine oxidation, in deamidation at Asn149 and in where the backbone had cleaved. A variant isolated from bacterially expressed preparations had its small C-terminal disulfide replaced by a non-reducible thioether, which the authors note falls in a region earlier mutagenesis had implicated in receptor binding, although the functional consequence was discussed rather than measured. Routine disulfide assignment is now done analytically for exactly this reason, because incorrect folding and disulfide scrambling are not detectable from a sequence read.[6,29,41]

Finally, the step this page cannot describe at molecular resolution is the one between binding and signalling, and the hormone's role in it is inferred rather than observed. Comparing liganded and unliganded receptor extracellular domains found no substantial conformational change on binding, and the full-length receptor could be activated with no ligand at all by inserting a defined number of alanine residues into its transmembrane segment, which argues that bringing two receptors together is not by itself the activating event. The later model, in which activation separates the two JAK2-binding motifs through a change from a parallel transmembrane helix pair to a left-handed crossover, was assembled from engineered constructs, resonance energy transfer, atomistic simulation and docking of separately determined domains. No deposited structure of a hormone-bound, membrane-spanning receptor with its kinase was located, and the hormone's contribution is attributed to the asymmetric placement of its two binding sites.[42,24]

Key papers on Somatropin

  1. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.

    de Vos AM, Ultsch M, Kossiakoff AA (1992), Science · X-ray crystallography

    The structure that defined the molecule: the four-helix bundle, the 1:2 stoichiometry and the two dissimilar binding faces, all in one paper.

  2. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis.

    Cunningham BC, Wells JA (1989), Science · Alanine-scanning mutagenesis

    The residue-level map of site 1, and a model of how to read a binding surface before any structure exists. It also found the one residue that hinders binding.

  3. A hot spot of binding energy in a hormone-receptor interface.

    Clackson T, Wells JA (1995), Science · Interface energetics

    The clearest statement of why a structural contact map is not an energy map: thirty contacts, two tryptophans, three quarters of the binding energy.

  4. Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization.

    Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA (2003), Protein Science · Binding kinetics of alanine mutants

    The counterpart for the second site, and the reason site 1 and site 2 should never be described in the same terms.

  5. Dimerization of human growth hormone by zinc.

    Cunningham BC, Mulkerrin MG, Wells JA (1991), Science · Metal binding and protein association

    The metal chemistry: stoichiometry, coordination geometry, the three side chains involved, and the effect on stability.

  6. Somatropin and its variants: structural characterization and methods of analysis.

    Bayol A, Bristow A, Charton E, Girard M, Jongen P (2004), Pharmeuropa Bio · Review of structural characterisation and analytical methods

    Read for identity rather than for mechanism: what somatropin is defined as, how it came to be characterised physicochemically rather than by bioassay, and why the methionyl form is a separate substance.

  7. Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone.

    Jiang H, Wu SL, Karger BL, Hancock WS (2009), Biotechnology Progress · Mass spectrometric characterisation

    The demonstration that the same sequence is not the same material, with the modification sites named.

References

  1. 1.UniProt Consortium. UniProtKB entry P01241 (SOMA_HUMAN), Somatotropin, Homo sapiens. UniProtKB. source · database record
  2. 2.de Vos AM, Ultsch M, Kossiakoff AA. (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 255:306-12. doi:10.1126/science.1549776 · abstract only
  3. 3.Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. (1991). Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science. 254:821-5. doi:10.1126/science.1948064 · abstract only
  4. 4.Clackson T, Wells JA. (1995). A hot spot of binding energy in a hormone-receptor interface. Science. 267:383-6. doi:10.1126/science.7529940 · abstract only
  5. 5.Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, Ross MJ, Miozzari G, Crea R, Seeburg PH. (1979). Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 281:544-8. doi:10.1038/281544a0 · abstract only
  6. 6.Jiang H, Wu SL, Karger BL, Hancock WS. (2009). Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone. Biotechnology Progress. 25:207-18. doi:10.1002/btpr.72 · abstract only
  7. 7.U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-Approved Drugs. Drugs@FDA database. source · database record
  8. 8.U.S. National Library of Medicine. (2026). DailyMed: somatropin (Sandoz Inc.) prescribing information, Indications and Usage. DailyMed. source · full text read
  9. 9.European Medicines Agency. (2026). Medicines: search for human medicines (centrally authorised medicines). European Medicines Agency medicines database. source · database record
  10. 10.Health Canada. (2026). Drug Product Database online query. Health Canada Drug Product Database. source · database record
  11. 11.United States Congress. (2026). 21 U.S. Code § 333: Penalties, subsection (e), Prohibited distribution of human growth hormone. United States Code. source · full text read
  12. 12.World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. source · full text read
  13. 13.US Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA human drug compounding. source · full text read
  14. 14.National Center for Advancing Translational Sciences. Global Substance Registration System record for SOMATROPIN, UNII NQX9KB6PCL. FDA Global Substance Registration System. source · database record
  15. 15.Bayol A, Bristow A, Charton E, Girard M, Jongen P. (2004). Somatropin and its variants: structural characterization and methods of analysis. Pharmeuropa Bio. 2004:35-45. PMID 15659284 · abstract only
  16. 16.Clackson T, Ultsch MH, Wells JA, de Vos AM. (1998). Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. Journal of Molecular Biology. 277:1111-28. doi:10.1006/jmbi.1998.1669 · abstract only
  17. 17.Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA. (2003). Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Protein Science. 12:1960-70. doi:10.1110/ps.03133903 · abstract only
  18. 18.Cunningham BC, Wells JA. (1989). High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 244:1081-5. doi:10.1126/science.2471267 · abstract only
  19. 19.Cunningham BC, Mulkerrin MG, Wells JA. (1991). Dimerization of human growth hormone by zinc. Science. 253:545-8. doi:10.1126/science.1907025 · abstract only
  20. 20.Cunningham BC, Bass S, Fuh G, Wells JA. (1990). Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 250:1709-12. doi:10.1126/science.2270485 · abstract only
  21. 21.Li CH, Dixon JS. (1971). Human pituitary growth hormone. 32. The primary structure of the hormone: revision. Archives of Biochemistry and Biophysics. 146:233-6. doi:10.1016/s0003-9861(71)80060-7 · abstract only
  22. 22.Niall HD, Hogan ML, Sauer R, Rosenblum IY, Greenwood FC. (1971). Sequences of pituitary and placental lactogenic and growth hormones: evolution from a primordial peptide by gene reduplication. Proceedings of the National Academy of Sciences of the United States of America. 68:866-70. doi:10.1073/pnas.68.4.866 · abstract only
  23. 23.Dieguez C, López M, Casanueva F. (2025). Hypothalamic GHRH. Reviews in Endocrine and Metabolic Disorders. 26:297-303. doi:10.1007/s11154-025-09951-y · abstract only
  24. 24.Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, Gardon O, Tunny KA, Blucher KM, Morton CJ, Parker MW, Sierecki E, Gambin Y, Gomez GA, Alexandrov K, Wilson IA, Doxastakis M, Mark AE, Waters MJ. (2014). Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 344:1249783. doi:10.1126/science.1249783 · abstract only
  25. 25.UniProt Consortium. UniProtKB entry P10912 (GHR_HUMAN), Growth hormone receptor, Homo sapiens. UniProtKB. source · database record
  26. 26.Arsene C, Schulze D, Röthke A, Thevis M, Henrion A. (2018). Growth hormone isoform-differential mass spectrometry for doping control purposes. Drug Testing and Analysis. 10:938-946. doi:10.1002/dta.2350 · abstract only
  27. 27.Vickers MH, Gilmour S, Gertler A, Breier BH, Tunny K, Waters MJ, Gluckman PD. (2009). 20-kDa placental hGH-V has diminished diabetogenic and lactogenic activities compared with 22-kDa hGH-N while retaining antilipogenic activity. American Journal of Physiology. Endocrinology and Metabolism. 297:E629-37. doi:10.1152/ajpendo.00221.2009 · abstract only
  28. 28.HUGO Gene Nomenclature Committee. HGNC:4261, GH1, growth hormone 1. HGNC. source · database record
  29. 29.Datola A, Richert S, Bierau H, Agugiaro D, Izzo A, Rossi M, Cregut D, Diemer H, Schaeffer C, Van Dorsselaer A, Giartosio CE, Jone C. (2007). Characterisation of a novel growth hormone variant comprising a thioether link between Cys182 and Cys189. ChemMedChem. 2:1181-9. doi:10.1002/cmdc.200700042 · abstract only
  30. 30.Walsh ST, Sylvester JE, Kossiakoff AA. (2004). The high- and low-affinity receptor binding sites of growth hormone are allosterically coupled. Proceedings of the National Academy of Sciences of the United States of America. 101:17078-83. doi:10.1073/pnas.0403336101 · abstract only
  31. 31.de Vos AM, Ultsch M, Kossiakoff AA. (1993). PDB 3HHR: human growth hormone and extracellular domain of its receptor, crystal structure of the complex. RCSB Protein Data Bank. doi:10.2210/pdb3hhr/pdb · database record
  32. 32.Chantalat L, Jones ND, Korber F, Navaza J, Pavlovsky AG. (1995). PDB 1HGU: the crystal structure of wild-type growth hormone at 2.5 angstrom resolution. RCSB Protein Data Bank. doi:10.2210/pdb1hgu/pdb · database record
  33. 33.Ultsch MH, Somers W, Kossiakoff AA, de Vos AM. (1994). The crystal structure of affinity-matured human growth hormone at 2 A resolution. Journal of Molecular Biology. 236:286-99. doi:10.1006/jmbi.1994.1135 · abstract only
  34. 34.Sundström M, Lundqvist T, Rödin J, Giebel LB, Milligan D, Norstedt G. (1996). PDB 1HWG: 1:2 complex of human growth hormone with its soluble binding protein, and PDB 1HWH, the 1:1 complex of the G120R mutant. RCSB Protein Data Bank. doi:10.2210/pdb1hwg/pdb · database record
  35. 35.Schiffer C, Ultsch M, Walsh S, Somers W, de Vos AM, Kossiakoff A. (2002). Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites. Journal of Molecular Biology. 316:277-89. doi:10.1006/jmbi.2001.5348 · abstract only
  36. 36.Atwell S, Ultsch M, De Vos AM, Wells JA. (1997). Structural plasticity in a remodeled protein-protein interface. Science. 278:1125-8. doi:10.1126/science.278.5340.1125 · abstract only
  37. 37.Somers W, Ultsch M, De Vos AM, Kossiakoff AA. (1994). The X-ray structure of a growth hormone-prolactin receptor complex. Nature. 372:478-81. doi:10.1038/372478a0 · abstract only
  38. 38.Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME. (2007). The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 46:2398-410. doi:10.1021/bi061958v · abstract only
  39. 39.ChEBI curators. ChEBI:37845, growth hormone. Chemical Entities of Biological Interest, read through the EBI Ontology Lookup Service. source · database record
  40. 40.ChEMBL curators. ChEMBL molecule record CHEMBL1201621, SOMATROPIN. ChEMBL, European Bioinformatics Institute. source · database record
  41. 41.Wu SL, Jiang H, Lu Q, Dai S, Hancock WS, Karger BL. (2009). Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. Analytical Chemistry. 81:112-22. doi:10.1021/ac801560k · abstract only
  42. 42.Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. (2005). Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nature Structural and Molecular Biology. 12:814-21. doi:10.1038/nsmb977 · abstract only

Scope. This entry describes chemistry, structure and published laboratory findings. It is not guidance on use of any kind.

Sources read: 35 distinct works. Researched 2026-11-03. Detailed review 2026-11-02. How this library is built.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.